Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary.

Clinical pharmacology and therapeutics·2017
Same author

Tyrosine kinase-targeting drugs-associated heart failure.

British journal of cancer·2017
Same author

The Influence of Race and Common Genetic Variations on Outcomes After Pediatric Heart Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near-Term Efforts in the Field.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Clinical pharmacology and therapeutics·2016
Same author

Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.

Clinical pharmacology and therapeutics·2015
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

Pediatric dose selection.

D R Abernethy1, G J Burckart

  • 1Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA. darrell.abernethy@fda.hhs.gov

Clinical Pharmacology and Therapeutics
|February 18, 2010
PubMed
Summary
This summary is machine-generated.

Determining pediatric drug doses often lacks sufficient pharmacokinetic data. Advanced modeling offers a promising solution for optimizing pediatric drug dosing strategies.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Development

Background:

  • Pediatric drug dosing frequently relies on limited pharmacokinetic data.
  • Traditional allometric scaling methods for pediatric dosing have limitations.
  • Existing methods may not fully utilize available drug-specific clinical pharmacokinetic information.

Purpose of the Study:

  • To highlight the challenges in pediatric drug dose selection.
  • To introduce modeling as a promising tool for pediatric pharmacokinetics.
  • To advocate for a structured approach in determining pediatric doses for new drugs.

Main Methods:

  • Review of traditional allometric scaling techniques in pediatric pharmacology.
  • Discussion of the limitations of current pediatric dosing strategies.
  • Exploration of pharmacokinetic modeling as an alternative approach.

Main Results:

  • Current methods for pediatric dose selection are often based on inadequate pharmacokinetic data.
  • Allometric scaling, while traditional, has inherent limitations for pediatric drug dosing.
  • Pharmacokinetic modeling presents a more adaptable and potentially optimal approach.

Conclusions:

  • There is a critical need for improved methods in pediatric drug dose selection.
  • Pharmacokinetic modeling shows significant promise for optimizing pediatric drug doses.
  • A structured, model-informed approach is essential for future pediatric therapeutic agent development.